Previous 10 | Next 10 |
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a fede...
AnaptysBio (NASDAQ: ANAB ): Q1 GAAP EPS of -$0.30 beats by $0.33 . More news on: AnaptysBio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in Third Quarter of 2020, Decided to Over-Enroll Trial Due to COVID-19 Additional Topline Data from GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate...
Outcomes from clinical trial results can propel a biotech's stock price positively or negatively, regardless of the size of the company. Currently, biotech investors are eagerly awaiting data from AnaptysBio (NASDAQ: ANAB) , which has a $435 million market cap, on a drug that recently fe...
New York, New York--(Newsfile Corp. - April 14, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities cl...
AnaptysBio (NASDAQ: ANAB) checks many boxes that make it an attractive biotech investment: It's got a sizable cash position, reputable pharma partners, and a promising drug pipeline. Throw in a depressed stock price and the company looks even more appealing. Is now the time for investors to ...
New York, New York--(Newsfile Corp. - April 3, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (NASDAQ: ANAB) ("Anaptys" or the "Company") of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities cla...
New York, New York--(Newsfile Corp. - April 1, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (NASDAQ: ANAB) ("Anaptys" or the "Company") of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securiti...
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been fil...
NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB) in the United States District Court for the Southern District o...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...